Evidence map›Paper›PMID 40939179›Full record

ArticleAnalytical chemistry2025

A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors.

Foroughsadat Absar, Brandon Novy, Edith Nagy, Evgeniy V Petrotchenko, Konstantin I Popov, Jason B Cross, Roopa Thapar, Christoph H Borchers

Abstract read
In one paragraph

Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Foroughsadat AbsarSegal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada.
Brandon NovyDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Edith NagyInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Evgeniy V PetrotchenkoSegal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada.ORCID 0000-0003-3612-9546
Konstantin I PopovDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jason B CrossInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Roopa ThaparInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Christoph H BorchersSegal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada.ORCID 0000-0003-2394-6512

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An important step in screening small-molecule libraries for drug discovery is hit prioritization and validation in order to rule out false positives. This is usually performed using biochemical and biophysical assays, so the development of orthogonal assays that are highly sensitive and can accelerate the hit-to-lead process would be valuable. Limited proteolysis combined with mass spectrometry (LiP-MS) is a technique used to study changes in protein structure upon ligand binding. In LiP-MS, proteins are exposed to low concentrations of proteases under native conditions. The resulting proteolytic patterns are sensitive to the protein structure near the cleavage site, which can change upon ligand binding. We have characterized the interaction of small-molecule inhibitors of the KRas G12D mutant oncoprotein by LiP-MS combined with molecular dynamics (MD). Intact mass spectrometry and top-down analysis were used to detect and identify KRas G12D cleavage products in the presence and absence of inhibitors, thereby locating the cleavage sites within the protein. Cleavage sites that were found to be protected upon compound binding correlated well with the switch II binding site. The degree of cleavage depended on the binding affinity and the presence of specific functional groups in the inhibitor's structure. A comparison of MD simulations for the ligand-free and ligand-bound proteins revealed the atomistic mechanisms by which the cleavage sites, located in flexible and disordered regions, were stabilized upon compound binding. We suggest that LiP-MS combined with MD (LiP-MS-MD) could be valuable in small-molecule screening campaigns and can be added to the current list of methods for high-quality hit selection in early stage drug discovery.

Indexed as

Mass SpectrometryMolecular Dynamics SimulationProto-Oncogene Proteins p21(ras)Small Molecule LibrariesDrug Evaluation, PreclinicalHumansLigandsProteolysisKRAS protein, humanLigandsProto-Oncogene Proteins p21(ras)Small Molecule Libraries

Identifiers

PMID40939179
PMCPMC12461684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.